vs

Side-by-side financial comparison of Ginkgo Bioworks Holdings, Inc. (DNA) and Hyperscale Data, Inc. (GPUS). Click either name above to swap in a different company.

Ginkgo Bioworks Holdings, Inc. is the larger business by last-quarter revenue ($33.4M vs $26.9M, roughly 1.2× Hyperscale Data, Inc.). On growth, Hyperscale Data, Inc. posted the faster year-over-year revenue change (38.4% vs -23.8%). Ginkgo Bioworks Holdings, Inc. produced more free cash flow last quarter ($-47.7M vs $-56.2M). Over the past eight quarters, Ginkgo Bioworks Holdings, Inc.'s revenue compounded faster (-6.2% CAGR vs -16.3%).

Ginkgo Bioworks Holdings, Inc. is an American biotech company founded in 2008 by five scientists from MIT, headed by Jason Kelly. The company specializes in using genetic engineering to produce bacteria with industrial applications for other biotech companies, saving other companies the cost of reproducing the initial stages of design in synthetic biology. The self-proclaimed "Organism Company" was one of the world's largest privately held biotech companies, valued at $4.2 billion in 2019. It...

Hyperscale Data, Inc. provides GPU-accelerated computing infrastructure and cloud solutions tailored for AI development, big data processing, and high-performance computing workloads. It primarily serves AI startups, large technology firms, and cloud service providers across North America and the Asia-Pacific region, delivering scalable, high-efficiency computing resources to support complex data processing needs.

DNA vs GPUS — Head-to-Head

Bigger by revenue
DNA
DNA
1.2× larger
DNA
$33.4M
$26.9M
GPUS
Growing faster (revenue YoY)
GPUS
GPUS
+62.2% gap
GPUS
38.4%
-23.8%
DNA
More free cash flow
DNA
DNA
$8.5M more FCF
DNA
$-47.7M
$-56.2M
GPUS
Faster 2-yr revenue CAGR
DNA
DNA
Annualised
DNA
-6.2%
-16.3%
GPUS

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
DNA
DNA
GPUS
GPUS
Revenue
$33.4M
$26.9M
Net Profit
$-30.1M
Gross Margin
14.5%
Operating Margin
-211.9%
-117.8%
Net Margin
-112.0%
Revenue YoY
-23.8%
38.4%
Net Profit YoY
-6670.3%
EPS (diluted)
$-1.41

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DNA
DNA
GPUS
GPUS
Q4 25
$33.4M
$26.9M
Q3 25
$38.8M
$24.3M
Q2 25
$49.6M
$25.9M
Q1 25
$48.3M
$25.0M
Q4 24
$43.8M
$19.4M
Q3 24
$89.0M
$31.1M
Q2 24
$56.2M
$17.8M
Q1 24
$37.9M
$38.4M
Net Profit
DNA
DNA
GPUS
GPUS
Q4 25
$-30.1M
Q3 25
$-80.8M
$-13.0M
Q2 25
$-60.3M
$-19.1M
Q1 25
$-91.0M
$-4.2M
Q4 24
$-445.0K
Q3 24
$-56.4M
$-25.5M
Q2 24
$-217.2M
$-33.9M
Q1 24
$-165.9M
$3.7M
Gross Margin
DNA
DNA
GPUS
GPUS
Q4 25
14.5%
Q3 25
25.8%
Q2 25
23.7%
Q1 25
21.1%
Q4 24
6.5%
Q3 24
27.5%
Q2 24
-21.3%
Q1 24
47.4%
Operating Margin
DNA
DNA
GPUS
GPUS
Q4 25
-211.9%
-117.8%
Q3 25
-231.8%
-57.8%
Q2 25
-132.1%
-39.2%
Q1 25
-184.1%
-25.5%
Q4 24
-236.3%
-46.8%
Q3 24
-62.0%
-79.2%
Q2 24
-396.7%
-151.4%
Q1 24
-469.1%
9.5%
Net Margin
DNA
DNA
GPUS
GPUS
Q4 25
-112.0%
Q3 25
-207.9%
-53.5%
Q2 25
-121.6%
-73.7%
Q1 25
-188.2%
-16.8%
Q4 24
-2.3%
Q3 24
-63.3%
-82.3%
Q2 24
-386.4%
-190.7%
Q1 24
-437.3%
9.7%
EPS (diluted)
DNA
DNA
GPUS
GPUS
Q4 25
$-1.41
Q3 25
$-1.45
$-0.39
Q2 25
$-1.10
$-2.66
Q1 25
$-1.68
Q4 24
$-1.91
$-8.78
Q3 24
$-1.08
$-24.82
Q2 24
$-4.23
$-37.81
Q1 24
$-3.32
$3.32

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DNA
DNA
GPUS
GPUS
Cash + ST InvestmentsLiquidity on hand
$422.6M
$13.1M
Total DebtLower is stronger
$83.1M
Stockholders' EquityBook value
$508.6M
$119.8M
Total Assets
$1.1B
$313.7M
Debt / EquityLower = less leverage
0.69×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DNA
DNA
GPUS
GPUS
Q4 25
$422.6M
$13.1M
Q3 25
$495.5M
$24.8M
Q2 25
$559.4M
$5.9M
Q1 25
$325.3M
$4.2M
Q4 24
$561.6M
$4.5M
Q3 24
$616.2M
$7.9M
Q2 24
$730.4M
$9.6M
Q1 24
$840.4M
$18.9M
Total Debt
DNA
DNA
GPUS
GPUS
Q4 25
$83.1M
Q3 25
$80.0M
Q2 25
$88.5M
Q1 25
$92.8M
Q4 24
$96.7M
Q3 24
$104.8M
Q2 24
$106.8M
Q1 24
$30.0M
Stockholders' Equity
DNA
DNA
GPUS
GPUS
Q4 25
$508.6M
$119.8M
Q3 25
$559.8M
$55.9M
Q2 25
$613.0M
$5.5M
Q1 25
$647.4M
$6.3M
Q4 24
$716.1M
$8.6M
Q3 24
$797.9M
$2.7M
Q2 24
$833.1M
$26.7M
Q1 24
$987.3M
$59.0M
Total Assets
DNA
DNA
GPUS
GPUS
Q4 25
$1.1B
$313.7M
Q3 25
$1.2B
$242.4M
Q2 25
$1.2B
$213.5M
Q1 25
$1.3B
$218.5M
Q4 24
$1.4B
$220.8M
Q3 24
$1.5B
$231.5M
Q2 24
$1.6B
$270.8M
Q1 24
$1.6B
$299.8M
Debt / Equity
DNA
DNA
GPUS
GPUS
Q4 25
0.69×
Q3 25
1.43×
Q2 25
16.06×
Q1 25
14.71×
Q4 24
11.19×
Q3 24
38.41×
Q2 24
4.00×
Q1 24
0.51×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DNA
DNA
GPUS
GPUS
Operating Cash FlowLast quarter
$-47.7M
$-37.7M
Free Cash FlowOCF − Capex
$-47.7M
$-56.2M
FCF MarginFCF / Revenue
-142.8%
-208.7%
Capex IntensityCapex / Revenue
0.0%
68.6%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-87.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DNA
DNA
GPUS
GPUS
Q4 25
$-47.7M
$-37.7M
Q3 25
$-31.6M
$-17.8M
Q2 25
$-40.3M
$-3.1M
Q1 25
$-51.5M
$-4.0M
Q4 24
$-42.4M
$-9.2M
Q3 24
$-103.5M
$3.7M
Q2 24
$-84.4M
$-3.7M
Q1 24
$-89.3M
$-10.2M
Free Cash Flow
DNA
DNA
GPUS
GPUS
Q4 25
$-47.7M
$-56.2M
Q3 25
$-20.6M
Q2 25
$-40.3M
$-3.5M
Q1 25
$-59.1M
$-6.8M
Q4 24
$-56.1M
$-9.3M
Q3 24
$-118.6M
$2.6M
Q2 24
$-111.4M
$-5.9M
Q1 24
$-96.0M
$-11.6M
FCF Margin
DNA
DNA
GPUS
GPUS
Q4 25
-142.8%
-208.7%
Q3 25
-84.5%
Q2 25
-81.2%
-13.5%
Q1 25
-122.4%
-27.3%
Q4 24
-128.0%
-47.6%
Q3 24
-133.2%
8.4%
Q2 24
-198.2%
-33.4%
Q1 24
-252.9%
-30.3%
Capex Intensity
DNA
DNA
GPUS
GPUS
Q4 25
0.0%
68.6%
Q3 25
0.0%
11.5%
Q2 25
0.1%
1.5%
Q1 25
15.8%
11.5%
Q4 24
31.3%
0.3%
Q3 24
16.9%
3.6%
Q2 24
48.1%
12.6%
Q1 24
17.7%
3.7%
Cash Conversion
DNA
DNA
GPUS
GPUS
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
-2.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DNA
DNA

Cell Engineering Segment$26.0M78%
Other$7.4M22%

GPUS
GPUS

Transferred Over Time$10.4M39%
Revenue From Mined Crypto Assets At Sentinum Owned And Operated Facilities$5.8M21%
Hotel And Real Estate Operations$4.8M18%
Other$4.0M15%
Turn On Green$2.0M7%

Related Comparisons